News archive
Showing 677 results
September 2016
-
Media ReleaseNovartis BAF312 reduced the risk of disability progression in pivotal phase III study in secondary progressive MS patients
-
Media ReleaseNovartis data finds relapsing MS patients on Gilenya® had greater treatment retention and satisfaction rates vs. injectable DMTs- In a well-controlled, randomized, open-label study, Gilenya patients had higher treatment retention rates at one year, 81.3% vs. those on injectable DMTs, 29.2% - Throughout the study almost 10…
-
Media ReleaseNovartis data finds relapsing MS patients on Gilenya® had greater treatment retention and satisfaction rates vs. injectable DMTs
July 2016
-
Media ReleaseNovartis announces FDA approval of Xolair® (omalizumab) for pediatric allergic asthma-- Extension of indication makes Xolair the first and only approved biologic for pediatric patients six years and older with uncontrolled moderate to severe persistent allergic asthma-- Asthma is one…
-
Media ReleaseNovartis announces FDA approval of Xolair® (omalizumab) for pediatric allergic asthma
June 2016
-
Media ReleaseLargest global psoriasis survey shows 85% of U.S. respondents faced social stigma like discrimination and humiliation because of their skin- Global survey, including more than 1,400 U.S. moderate-to-severe psoriasis patients, is the first to look at perceptions of clear skin1- Despite the significant impact of living with the disease,…
-
Media ReleaseLargest global psoriasis survey shows 85% of U.S. respondents faced social stigma like discrimination and humiliation because of their skin
-
Media ReleaseTimely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA CardiologyFindings are first to quantify magnitude of potential survival benefits if Entresto were prescribed to all eligible US HFrEF patients (as defined by authors)(1)Cardiology experts highlight risk of…
-
Media ReleaseTimely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology
-
Media ReleaseNovartis data show Gilenya® had significantly greater patient retention compared to iDMTs in relapsing-remitting MS- Data demonstrate at 12 months, 81% of patients started on fingolimod stay on therapy vs. 29% started on injectable disease-modifying therapies (iDMTs)(1)- Injectable disease-modifying therapies are…
-
Media ReleaseNovartis data show Gilenya® had significantly greater patient retention compared to iDMTs in relapsing-remitting MS